Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 513-519

  Tran, Jonathan Q ^a,d   Di Cicco, Robert A ^a   Sheth, Sunita B ^a   Tucci, Marcella ^b   Peng, Lana ^b   Jorkasky, Diane K ^a   Hursting, Marcie J ^c   Benincosa, Lisa J ^b  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^d Millard Fillmore Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; CYTOCHROME P450; ERYTHROMYCIN;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; ANTITHROMBINS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; ERYTHROMYCIN; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS;

EID: 0032765276     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fitzgerald D, Murphy N: Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996;7:455-458.
2. Hursting MJ, Alford KL, Becker JCP, et al: Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Sem Thromb Hemostas 1997;23:503-516.
3. Lewis BE, Walenga JM, Wallis DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Sem Thromb Hemostas 1997;23:197-202.
4. Ahsan A, Ahmad S, Iqbal O, et al: Comparative studies on the biochemical and pharmacological properties of a major metabolite of argatroban (M1): potential clinical implications. Thromb Haemost 1997;78(Suppl. 92):PS-370.
5. Iida S, Komatsu T, Hirano T, et al: Pharmacokinetic studies of argipidine (MD-805) in dogs and rabbits: blood or plasma level profile, metabolism, excretion and accumulation after single or consecutive intravenous administration of argipidine. Oyo Yakuri 1986;32: 1117-1127.
6. Hursting MJ, Joffrion JL, Brooks RL: Effects of age and gender on the pharmacokinetics and pharmacodynamics of argatroban in healthy volunteers. Blood 1996;88(Suppl. 1):82b.
7. Hursting MJ, Joffrion JL, Brooks RL, Swan SK: Effect of renal function on the pharmacokinetics and pharmacodynamics of argatroban (a direct thrombin inhibitor). Blood 1996;88(Suppl. 1):167a.
8. Periti P, Mazzei T, Mini E, Novelli A: Pharmacokinetic drug interaction with Macrolides. Clin Pharmacokin 1992;23:106-131.
9. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-238.
10. Yee GC, McGuire TR: Pharmacokinetic drug interactions with cyclosporin. Clin Pharmacokin 1990;19:319-332, 400-415.
11. Bailey DG, Bend JR, Arnold JM, Tran LT, Spence JD: Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996;60:25-33.
12. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al: A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
13. Luurila H, Olkkola KT, Neuvonen PJ: Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacol Toxicol 1996;78:117-122.
14. Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83:1510-1518.
15. Slaughter RL, Edwards DJ: Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-624.
16. Michalets EL: Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
17. Honig PK, WorthamDC, Zamani K, Conner DP, Mullin JC, Cantilena LR: Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-1518.
18. Wysowski DK, Bacsanyi J: Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-291.
19. Patnaik RN, Lesko LJ, Chen ML, et al: Individual bioequivalence: new concepts in the statistical assessment of bioequivalent metrics. Clin Pharmacokinet 1997;33:1-6.
20. Yuan R, Balian JD, Svadjian R, et al: Role of in vitro metabolic interactions in the conduct of drug-drug interaction studies. Clin Pharmacol Ther 1998;63:A218.